Saudi Arabia In Vitro Diagnostics Market, By Product (Instruments, Reagents, Software & Services), By Technology (Immunoassay, Hematology, Clinical Chemistry, Molecular Diagnostics, Microbiology, Others), By Application (Infectious Diseases, Diabetes, Oncology, Cardiology, Nephrology, Others), By End User (Hospitals & Clinics, Diagnostic Centers & Laboratories, Others), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

Saudi Arabia In Vitro Diagnostics Market was valued at USD 724.03 Million in 2024 and is expected to reach USD 920.94 Million by 2030 with a CAGR of 4.05%. In Vitro Diagnostics (IVD) refers to a category of medical tests and diagnostic procedures that are performed on biological samples taken from the human body, such as blood, urine, tissue, and other bodily fluids or specimens, outside of the living organism. The term "in vitro" is Latin for "in glass," and it signifies that these tests are conducted in a controlled laboratory environment, typically in test tubes, Petri dishes, or other laboratory equipment. IVD tests are designed to provide critical information about a patient's health, including the presence or absence of diseases, infections, and various medical conditions. These tests play a vital role in disease diagnosis, monitoring, and management, as well as in screening for early disease detection. They are used in various healthcare settings, including hospitals, clinics, laboratories, and even at the point of care (POC) by healthcare providers. IVD covers a broad range of diagnostic categories, including clinical chemistry, hematology, microbiology, immunology, pathology, genetics, and more. Each category focuses on specific types of tests and diagnostic procedures. Samples for IVD tests can include blood, urine, saliva, tissue, cerebrospinal fluid, and other biological materials. The choice of sample depends on the type of test and the information needed for diagnosis.

Like many countries, Saudi Arabia is experiencing an aging population, which is more susceptible to health issues. This demographic shift boosts the demand for diagnostic tests, particularly in geriatric care. Continuous advancements in IVD technology, including molecular diagnostics and point-of-care testing, offer more accurate and rapid testing solutions, attracting both healthcare providers and patients. Increasing awareness among the population about the benefits of early disease detection and regular health check-ups is driving the demand for IVD tests. The COVID-19 pandemic accelerated the adoption of telehealth and digital health solutions. This has created opportunities for IVD companies to offer remote diagnostic testing and monitoring. Saudi Arabia has been increasing its healthcare spending to enhance its healthcare infrastructure and services. This investment provides a favorable environment for the IVD market to expand and innovate.

Key Market Drivers

Rising Burden of Chronic and Infectious Diseases

The escalating prevalence of chronic and infectious diseases in Saudi Arabia is one of the most significant forces propelling the growth of the In Vitro Diagnostics (IVD) market. In Saudi Arabia, chronic diseases represent a significant public health challenge, with particularly high rates of conditions such as diabetes, hypertension, and obesity. Current data indicates that diabetes affects approximately 14.8% of men and 11.7% of women, while hypertension is prevalent in 17.7% of men and 12.5% of women. These figures highlight the urgent need for sustained investment in early detection, preventive healthcare, and ongoing diagnostic monitoring key areas where the In Vitro Diagnostics (IVD) market plays a critical role. This trend is reshaping healthcare demand, diagnostic infrastructure, and investment priorities across the Kingdom. Saudi Arabia is witnessing a substantial rise in chronic, non-communicable diseases (NCDs), including Saudi Arabia ranks among the countries with the highest diabetes prevalence worldwide, with over 18% of its adult population affected. Increasing rates of obesity, hypertension, and sedentary lifestyles have led to a surge in cardiovascular conditions, which require constant diagnostic monitoring through lipid profiles, cardiac biomarkers, and enzyme assays. Early detection and routine screening are becoming more common due to increasing cancer incidence, thereby boosting demand for molecular diagnostics, tumor markers, and genetic testing. In 2020, Saudi Arabia reported an age-standardized incidence rate (ASR) of 96.5 cancer cases per 100,000 population, positioning it as a major contributor to the regional cancer burden. Notably, nearly two-thirds of all cancer cases within the Gulf Cooperation Council (GCC) countries were recorded in Saudi Arabia. These chronic conditions necessitate routine, long-term testing, which directly increases the consumption of IVD reagents, kits, and analyzers in both hospital and private lab settings.

The emergence and re-emergence of infectious diseases, including outbreaks of COVID-19, MERS-CoV, influenza, and other respiratory viruses, have significantly heightened the demand for rapid and accurate diagnostic testing. Saudi Arabia experienced a sharp surge in COVID-19 cases in the early stages of the pandemic, with infections escalating from a single case to 101,914 within a matter of months. Although the daily case count began to stabilize after approximately two months, the virus showed higher prevalence among adults and males. According to a study conducted by the National Institutes of Health (NIH), the country recorded an overall recovery rate of 71.4%, emphasizing the critical role of diagnostic testing in managing public health outcomes and informing response strategies. During the COVID-19 pandemic, the use of RT-PCR and antigen tests soared, reinforcing the importance of advanced molecular diagnostics in disease management. Post-pandemic, there is an institutional shift toward preparedness and surveillance, creating sustained demand for infectious disease testing solutions, including multiplex panels and point-of-care devices. This shift has laid a strong foundation for ongoing investments in diagnostics, even beyond emergency scenarios. The growing burden of disease is not only driving treatment-related diagnostics but is also fostering a culture of preventive healthcare. Early detection is now recognized as key to reducing long-term healthcare costs and improving patient outcomes. Employers, insurers, and healthcare providers are increasingly advocating for routine screening and health check-up programs, especially for lifestyle-related diseases. This has led to higher demand for biochemical, immunoassay, and hematology-based IVD tests, particularly in primary healthcare and outpatient clinics.

Aging Population and Population Growth

The demographic landscape of Saudi Arabia is undergoing a substantial transformation, characterized by both steady population growth and an increasing proportion of elderly citizens. These shifts are significantly influencing healthcare demand and are among the key drivers of growth in the In Vitro Diagnostics (IVD) market. Saudi Arabia’s total population continues to grow, driven by natural birth rates and urbanization. Between 2020 and 2022, the proportion of Saudi Arabia’s population aged 60 and above ranged from 5.59% to 6.9% of the total population. This gradual increase in the elderly demographic underscores a growing demand for age-specific healthcare services and chronic disease management, further driving the need for advanced In Vitro Diagnostics (IVD) solutions across the Kingdom. According to government data and global health organizations, the elderly population in Saudi Arabia is expected to double in the coming decades, a trend that carries major implications for the diagnostic industry. This demographic evolution exerts a twofold impact: It increases the volume of diagnostic testing required across all age groups. It amplifies demand for complex and continuous diagnostics, especially for age-related and chronic conditions.  As the population ages, there is a growing emphasis on preventive care and early detection. Healthcare systems, both public and private, are increasingly encouraging: Annual health check-ups, Cancer screening programs, Monitoring of risk factors in the elderly. This shift toward early and routine diagnostics supports steady demand for IVD services, including hematology, immunoassays, and clinical chemistry testing. An expanding and aging population is placing significant pressure on Saudi Arabia’s healthcare infrastructure, prompting Expansion of hospitals and diagnostic laboratories, Investment in high-throughput and automated IVD equipment, Decentralization of testing services through point-of-care diagnostics. This infrastructure development is creating new revenue channels for IVD manufacturers and solution providers, both domestic and international.

Download Free Sample Report

Key Market Challenges

Regulatory Complexity and Lengthy Approval Processes

Despite recent efforts to streamline medical device regulations, navigating the regulatory landscape in Saudi Arabia remains a key challenge for IVD manufacturers and distributors. The Saudi Food and Drug Authority (SFDA) requires strict compliance with documentation, testing, and certification protocols before granting market access. Delays in approval timelines and frequent regulatory updates can hinder the speed-to-market for new diagnostic technologies. International companies often face additional hurdles related to product localization, language requirements, and coordination with local partners for distribution and licensing. This regulatory burden can discourage innovation, delay the introduction of advanced testing methods, and increase operational costs particularly for small to mid-sized players seeking market entry.

Limited Local Manufacturing and Overdependence on Imports

Saudi Arabia relies heavily on imported IVD products, equipment, and testing kits, primarily sourced from North America, Europe, and East Asia. This overdependence on foreign suppliers makes the market vulnerable to global supply chain disruptions, currency fluctuations, and extended lead times factors that became especially evident during the COVID-19 pandemic. The absence of a robust local manufacturing base restricts the country's ability to respond swiftly to domestic diagnostic needs and increases healthcare costs. Moreover, local players often lack the R&D capabilities, technical expertise, and infrastructure required to develop and scale up innovative IVD solutions. This dependency limits Saudi Arabia’s self-sufficiency and hinders the long-term growth of a resilient, sustainable diagnostic ecosystem.

Key Market Trends

Expansion of AI and Big Data in Healthcare

Artificial Intelligence (AI) and Big Data analytics are becoming fundamental to Vietnam’s eHealth ecosystem. These technologies are reshaping diagnostics, predictive healthcare, and operational efficiency, enabling providers to deliver more accurate, timely, and cost-effective medical services.

AI-driven solutions are increasingly being integrated into radiology, pathology, and disease detection. Machine learning algorithms enhance early-stage cancer detection, cardiovascular risk assessment, and diabetic retinopathy diagnosis, improving clinical decision-making and reducing dependency on specialist physicians. Big Data analytics enables risk assessment models that help predict disease outbreaks, patient deterioration, and treatment responses. By analyzing historical health data, AI can recommend personalized treatment plans, reducing hospital readmissions and optimizing resource allocation. AI is streamlining hospital management by automating appointment scheduling, patient triage, and administrative workflows. Chatbots and AI-driven customer service platforms are being deployed to handle patient inquiries, improving engagement while reducing operational costs.

AI and Big Data will drive the next wave of healthcare efficiency, helping Vietnam’s hospitals and clinics handle growing patient volumes while ensuring faster, data-driven decision-making. The adoption of AI-powered tools will accelerate as providers seek to reduce diagnostic errors, enhance treatment outcomes, and lower healthcare costs.

Growth of Digital Therapeutics and Remote Patient Monitoring

The rise of digital therapeutics (DTx) and remote patient monitoring (RPM) is transforming Vietnam’s approach to chronic disease management and post-treatment care. These solutions provide continuous, tech-enabled medical supervision, reducing hospital dependency and improving long-term patient outcomes.

Digital therapeutics are software-driven treatments designed to supplement or replace traditional medication. In Vietnam, mobile-based DTx solutions are being developed for diabetes management, mental health support, and rehabilitation programs. These tools provide behavioral coaching, medication adherence reminders, and real-time health tracking to empower patients in self-managing their conditions. Smartwatches, biosensors, and IoT-enabled medical devices are gaining traction, enabling continuous monitoring of vital signs such as heart rate, blood pressure, glucose levels, and oxygen saturation. This is particularly beneficial for elderly patients, post-surgery recovery, and high-risk populations who require ongoing medical supervision. Digital therapeutics platforms now offer physical therapy, cognitive rehabilitation, and post-stroke recovery programs through AI-driven virtual assistants and interactive exercises. These innovations reduce the need for frequent hospital visits, making healthcare more convenient and accessible.

The shift toward preventive and long-term digital health solutions will reduce the burden on Vietnam’s hospitals while improving patient engagement. As the country’s chronic disease prevalence rises, integrating DTx and RPM into standard care models will be essential for improving treatment adherence and overall population health.

Segmental Insights

Product Insights

Based on the category of Product, Reagent segment emerges as the fastest growing segment in the Saudi Arabia IVD Market and is predicted to continue expanding over the coming years. Reagents are fundamental components of diagnostic tests. They consist of various substances, such as chemicals, antibodies, or enzymes, that interact with patient samples to produce a measurable signal. Nearly all IVD tests, from blood tests to molecular diagnostics, rely on reagents for accurate and specific results. Many routine diagnostic tests, such as blood chemistry, haematology, and immunoassays, depend on reagents. These tests are commonly performed in healthcare settings to assess a patient's overall health and to diagnose various medical conditions. Reagents are crucial for testing infectious diseases, including viral and bacterial infections. The demand for such tests, especially considering the COVID-19 pandemic, has significantly increased the prominence of the Reagent segment. Reagents are integral to the management of chronic diseases such as diabetes, cardiovascular conditions, and autoimmune disorders. Continuous monitoring of these conditions requires regular testing, which drives the demand for reagents. Reagents are used in point-of-care testing, which has gained importance due to its rapid results and convenience. These tests can be performed in various healthcare settings, including clinics and physician offices. These factors are expected to drive the growth of this segment.

Application Insights

Based on category of Application, Cardiology segment dominated the Saudi Arabia In Vitro Diagnostics Market and is predicted to continue expanding over the coming years.  Cardiovascular diseases, including heart disease and hypertension, are major health concerns in Saudi Arabia. These conditions are leading causes of morbidity and mortality in the country. The high prevalence of cardiovascular diseases necessitates a significant number of diagnostic tests for risk assessment, diagnosis, and ongoing monitoring. An aging population is more susceptible to cardiovascular diseases. Saudi Arabia, like many other countries, has been experiencing demographic changes with a growing elderly population. This demographic shift has contributed to an increased demand for cardiovascular diagnostic tests. Unhealthy lifestyle factors, such as sedentary behavior, poor diet, and smoking, have been on the rise in Saudi Arabia. These factors are known contributors to heart diseases, making it essential to diagnose and manage cardiovascular conditions. There has been an increased awareness of the importance of cardiovascular health and the benefits of early detection and management of heart-related conditions. This has led to more individuals seeking diagnostic tests, especially for risk assessment and preventive measures. The Saudi government has launched various healthcare initiatives aimed at tackling non-communicable diseases, including cardiovascular diseases. These initiatives often involve screening programs and diagnostic campaigns, further boosting the demand for cardiovascular IVD tests.

Download Free Sample Report

Regional Insights

The Northern & Central region emerged as the largest market in the Saudi Arabia In Vitro Diagnostics Market in 2024. These regions are home to some of the most densely populated cities in Saudi Arabia, including the capital city, Riyadh, which is in the Central region. Higher population density typically correlates with a greater demand for healthcare services, including diagnostic testing. Northern and Central regions have a concentration of major healthcare facilities, including hospitals, clinics, and diagnostic centers. These healthcare institutions are more likely to offer a wide range of diagnostic tests and services, contributing to a larger share of the IVD market. Urban areas in these regions tend to have better healthcare infrastructure and access to medical services. As urbanization continues to increase, the demand for diagnostic tests grows, driven by lifestyle-related diseases and access to better healthcare facilities. The Northern and Central regions are economically vibrant, with a higher standard of living and greater economic activities. This can result in increased healthcare spending and the ability to access a broader range of medical services, including IVD tests. These regions are more likely to host educational institutions and research centers, which play a role in advancing medical knowledge and innovation. This environment can lead to the adoption of the latest diagnostic technologies and practices.

Recent Developments

• In December 2022, Quidel Corporation and Ortho Clinical Diagnostics Holdings plc have recently announced a definitive agreement, whereby Quidel will acquire Ortho, a major player in the in vitro diagnostics industry. The deal involves a purchase price of $24.68 per share of Ortho's common stock, to be paid using a combination of cash and newly issued shares in the merged entity. This offer represents a 25% premium over Ortho's closing stock price on December 22, 2021, resulting in an equity value of approximately $6.0 billion. The transaction is anticipated to be completed in the first half of fiscal year 2022, pending the fulfilment of standard closing conditions. This acquisition positions Quidel to tap into emerging markets by leveraging telehealth technology and digital health capabilities, all while utilizing Ortho's robust customer relationships to enhance patient access to point-of-care diagnostic products.

Key Market Players

• Altona Diagnostics GmbH
• Beckman Coulter, Inc.
• Siemens Healthineers AG
• OncoDNA SA
• Vela Diagnostics (Nile Science Corporation)
• Abbott Laboratories, Inc.
• Becton, Dickinson, and Company
• F. Hoffmann-La Roche AG
• Thermo Fischer Scientific, Inc.
• Sysmex Corporation

Report Scope:

In this report, the Saudi Arabia In Vitro Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

•    Saudi Arabia In Vitro Diagnostics Market, By Product:

o   Instruments

o   Reagent

o   Software & Services

•    Saudi Arabia In Vitro Diagnostics Market, By Technology:

o   Immunoassay

o   Hematology

o   Clinical Chemistry

o   Molecular Diagnostic

o    Microbiology

o   Others

• Saudi Arabia In Vitro Diagnostics Market, By Application:

o   Infectious Diseases

o   Diabetes

o   Oncology

o   Cardiology

o   Nephrology

o   Others

• Saudi Arabia In Vitro Diagnostics Market, By End-User:

o   Hospitals & Clinics

o   Diagnostic Centers & Laboratories

o   Others

• Saudi Arabia In Vitro Diagnostics Market, By region:

o   Eastern

o   Western

o   Northern & Central

o   Southern

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Saudi Arabia In Vitro Diagnostics   Market.

Available Customizations:

Saudi Arabia In Vitro Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Saudi Arabia In Vitro Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com